Access and resources
Now available through
SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor
indicated for the treatment of chronic hepatitis C (CHC) as a component of a combination
antiviral treatment regimen.
- SOVALDI efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4
infection, including those with hepatocellular carcinoma meeting Milan criteria
(awaiting liver transplantation) and those with HCV/HIV-1 co-infection
- Monotherapy of SOVALDI is not recommended.
- Treatment regimen and duration are dependent on both viral genotype and patient
- Treatment response varies based on baseline host and viral factors.
Important Safety Information
- SOVALDI combination treatment with ribavirin or with peginterferon alfa plus ribavirin
is contraindicated in women who are pregnant or may become pregnant and men whose
female partners are pregnant because of the risk for birth defects and fetal death
associated with ribavirin. Contraindications to peginterferon alfa and ribavirin
also apply to SOVALDI combination treatment. Refer to the prescribing information
of peginterferon alfa and ribavirin for a list of their contraindications.
Warnings and Precautions
- Pregnancy: Use with Ribavirin or Peginterferon Alfa/Ribavirin: Ribavirin
therapy should not be started unless a report of a negative pregnancy test has been
obtained immediately prior to initiation of therapy. Female patients of childbearing
potential and their male partners must use 2 forms of non-hormonal contraception
during treatment and for at least 6 months after treatment has concluded. Routine
monthly pregnancy tests must be performed during this time. Refer to the prescribing
information for ribavirin.
- Use with Potent P-gp Inducers: Rifampin and St. John's wort should not be
used with SOVALDI as they may significantly decrease sofosbuvir plasma concentration,
reducing its therapeutic effect.
Most common (≥20%, all grades) adverse reactions for:
- SOVALDI + peginterferon alfa + ribavirin combination therapy were fatigue, headache,
nausea, insomnia, and anemia
- SOVALDI + ribavirin combination therapy were fatigue and headache
Please see full Prescribing Information by clicking heretapping here.
- In addition to rifampin and St. John's wort, coadministration of SOVALDI is not
recommended with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin,
rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease
the concentration of sofosbuvir, reducing its therapeutic effect.